Aytu Bioscience Presentation Now Available for On-Demand Viewing

Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation

ENGLEWOOD, Colo., Dec, 5, 2016 /CNW/ -- Aytu Bioscience Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that the December 1 presentation from Chief Executive Officer Josh Disbrow, is now available for on-demand viewing at VirtualInvestorConferences.com.

LINK: http://tinyurl.com/1201postpr 

Aytu Bioscience's presentation will be available 24/7 for 90 days. Investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.

Aytu Corporate Highlights:

  • Executed commercial-focused business strategy since its founding in 2015, acquiring three FDA-approved, revenue-generating urology products, including Natesto®, the only FDA-approved nasally-administered testosterone product and only topically applied testosterone product without a black box safety warning (launched in late July 2016)
  • Demonstrated strong Natesto prescription growth during early commercialization, rapidly surpassing previous benchmarks for new and total prescriptions, and grew the number of unique Natesto prescribers
  • Built and expanded the Company's commercial infrastructure, including proven commercial leadership and a nationwide specialty sales force
  • Grew annual revenues nearly ten-fold during fiscal year 2016; Increased revenue additionally by 42% in first fiscal quarter 2017 (ended September 30, 2016)
  • Recently raised $8.6 million in public offering of common stock and warrants

About Aytu BioScience, Inc.
Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products in the field of urology. The Company currently markets three products: Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate specific membrane antigen (PSMA) for prostate cancer detection and staging, and Primsol® (trimethoprim hydrochloride), the only FDA-approved trimethoprim-only oral solution for urinary tract infections. Additionally, Aytu is developing MiOXSYS™, a novel, rapid semen analysis system with the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress. MiOXSYS is commercialized outside the U.S. where it is a CE Marked, Health Canada cleared product, and Aytu is conducting U.S.-based clinical trials in pursuit of 510k de novo medical device clearance by the FDA. Aytu's strategy is to continue building its portfolio of revenue-generating urology products, leveraging its focused commercial team and expertise to build leading brands within well-established markets. For more information, visit http://aytubio.com

Logo - http://photos.prnewswire.com/prnh/20160129/327291LOGO

SOURCE Aytu BioScience Inc.

For further information: For Investors & Media: PCG Advisory Group, Stephanie Prince, Managing Director, sprince@pcgadvisory.com, (646) 762-4518; VirtualInvestorConferences.com: Bradley H. Smith, Director of Marketing, IR and Compliance Services,PR Newswire, +1.201.947.7157, bradley.smith@prnewswire.com, http://aytubio.com

Organization Profile

Aytu BioScience Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890